267 related articles for article (PubMed ID: 23048024)
1. Discovery of AZD3839, a potent and selective BACE1 inhibitor clinical candidate for the treatment of Alzheimer disease.
Jeppsson F; Eketjäll S; Janson J; Karlström S; Gustavsson S; Olsson LL; Radesäter AC; Ploeger B; Cebers G; Kolmodin K; Swahn BM; von Berg S; Bueters T; Fälting J
J Biol Chem; 2012 Nov; 287(49):41245-57. PubMed ID: 23048024
[TBL] [Abstract][Full Text] [Related]
2. Population pharmacokinetic and pharmacodynamic analysis of plasma Aβ40 and Aβ42 following single oral doses of the BACE1 inhibitor AZD3839 to healthy volunteers.
Quartino A; Huledal G; Sparve E; Lüttgen M; Bueters T; Karlsson P; Olsson T; Paraskos J; Maltby J; Claeson-Bohnstedt K; Lee CM; Alexander R; Fälting J; Paulsson B
Clin Pharmacol Drug Dev; 2014 Sep; 3(5):396-405. PubMed ID: 27129013
[TBL] [Abstract][Full Text] [Related]
3. Population PKPD modeling of BACE1 inhibitor-induced reduction in Aβ levels in vivo and correlation to in vitro potency in primary cortical neurons from mouse and guinea pig.
Janson J; Eketjäll S; Tunblad K; Jeppsson F; Von Berg S; Niva C; Radesäter AC; Fälting J; Visser SA
Pharm Res; 2014 Mar; 31(3):670-83. PubMed ID: 24092053
[TBL] [Abstract][Full Text] [Related]
4. AZ-4217: a high potency BACE inhibitor displaying acute central efficacy in different in vivo models and reduced amyloid deposition in Tg2576 mice.
Eketjäll S; Janson J; Jeppsson F; Svanhagen A; Kolmodin K; Gustavsson S; Radesäter AC; Eliason K; Briem S; Appelkvist P; Niva C; Berg AL; Karlström S; Swahn BM; Fälting J
J Neurosci; 2013 Jun; 33(24):10075-84. PubMed ID: 23761903
[TBL] [Abstract][Full Text] [Related]
5. The selective BACE1 inhibitor VIa reduces amyloid-β production in cell and mouse models of Alzheimer's disease.
Cheng X; Zhou Y; Gu W; Wu J; Nie A; Cheng J; Zhou J; Zhou W; Zhang Y
J Alzheimers Dis; 2013; 37(4):823-34. PubMed ID: 23948917
[TBL] [Abstract][Full Text] [Related]
6. Design and synthesis of β-site amyloid precursor protein cleaving enzyme (BACE1) inhibitors with in vivo brain reduction of β-amyloid peptides.
Swahn BM; Kolmodin K; Karlström S; von Berg S; Söderman P; Holenz J; Berg S; Lindström J; Sundström M; Turek D; Kihlström J; Slivo C; Andersson L; Pyring D; Rotticci D; Ohberg L; Kers A; Bogar K; von Kieseritzky F; Bergh M; Olsson LL; Janson J; Eketjäll S; Georgievska B; Jeppsson F; Fälting J
J Med Chem; 2012 Nov; 55(21):9346-61. PubMed ID: 22924815
[TBL] [Abstract][Full Text] [Related]
7. Identification of a BACE1 Binding Peptide Candidate for the Prevention of Amyloid Beta in Alzheimer's Disease.
Read J; Suphioglu C
Cell Physiol Biochem; 2019; 53(2):413-428. PubMed ID: 31415717
[TBL] [Abstract][Full Text] [Related]
8. Robust central reduction of amyloid-β in humans with an orally available, non-peptidic β-secretase inhibitor.
May PC; Dean RA; Lowe SL; Martenyi F; Sheehan SM; Boggs LN; Monk SA; Mathes BM; Mergott DJ; Watson BM; Stout SL; Timm DE; Smith Labell E; Gonzales CR; Nakano M; Jhee SS; Yen M; Ereshefsky L; Lindstrom TD; Calligaro DO; Cocke PJ; Greg Hall D; Friedrich S; Citron M; Audia JE
J Neurosci; 2011 Nov; 31(46):16507-16. PubMed ID: 22090477
[TBL] [Abstract][Full Text] [Related]
9. The cysteine protease inhibitor, E64d, reduces brain amyloid-β and improves memory deficits in Alzheimer's disease animal models by inhibiting cathepsin B, but not BACE1, β-secretase activity.
Hook G; Hook V; Kindy M
J Alzheimers Dis; 2011; 26(2):387-408. PubMed ID: 21613740
[TBL] [Abstract][Full Text] [Related]
10. Discovery of AM-6494: A Potent and Orally Efficacious β-Site Amyloid Precursor Protein Cleaving Enzyme 1 (BACE1) Inhibitor with in Vivo Selectivity over BACE2.
Pettus LH; Bourbeau MP; Bradley J; Bartberger MD; Chen K; Hickman D; Johnson M; Liu Q; Manning JR; Nanez A; Siegmund AC; Wen PH; Whittington DA; Allen JR; Wood S
J Med Chem; 2020 Mar; 63(5):2263-2281. PubMed ID: 31589043
[TBL] [Abstract][Full Text] [Related]
11. Combining an amyloid-beta (Aβ) cleaving enzyme inhibitor with a γ-secretase modulator results in an additive reduction of Aβ production.
Strömberg K; Eketjäll S; Georgievska B; Tunblad K; Eliason K; Olsson F; Radesäter AC; Klintenberg R; Arvidsson PI; von Berg S; Fälting J; Cowburn RF; Dabrowski M
FEBS J; 2015 Jan; 282(1):65-73. PubMed ID: 25303711
[TBL] [Abstract][Full Text] [Related]
12. A series of molecular modeling techniques to reveal selective mechanisms of inhibitors to β-Site amyloid precursor protein cleaving enzyme 1 (BACE1) and β-site amyloid precursor protein cleaving enzyme 2 (BACE2).
Li S; Zhao H; Li J; Hao J; Yu H
J Biomol Struct Dyn; 2021 May; 39(8):2824-2837. PubMed ID: 32276567
[TBL] [Abstract][Full Text] [Related]
13. Spirocyclic β-site amyloid precursor protein cleaving enzyme 1 (BACE1) inhibitors: from hit to lowering of cerebrospinal fluid (CSF) amyloid β in a higher species.
Hunt KW; Cook AW; Watts RJ; Clark CT; Vigers G; Smith D; Metcalf AT; Gunawardana IW; Burkard M; Cox AA; Geck Do MK; Dutcher D; Thomas AA; Rana S; Kallan NC; DeLisle RK; Rizzi JP; Regal K; Sammond D; Groneberg R; Siu M; Purkey H; Lyssikatos JP; Marlow A; Liu X; Tang TP
J Med Chem; 2013 Apr; 56(8):3379-403. PubMed ID: 23537249
[TBL] [Abstract][Full Text] [Related]
14. Prevention of tau increase in cerebrospinal fluid of APP transgenic mice suggests downstream effect of BACE1 inhibition.
Schelle J; Häsler LM; Göpfert JC; Joos TO; Vanderstichele H; Stoops E; Mandelkow EM; Neumann U; Shimshek DR; Staufenbiel M; Jucker M; Kaeser SA
Alzheimers Dement; 2017 Jun; 13(6):701-709. PubMed ID: 27750032
[TBL] [Abstract][Full Text] [Related]
15. AZD3293: A Novel, Orally Active BACE1 Inhibitor with High Potency and Permeability and Markedly Slow Off-Rate Kinetics.
Eketjäll S; Janson J; Kaspersson K; Bogstedt A; Jeppsson F; Fälting J; Haeberlein SB; Kugler AR; Alexander RC; Cebers G
J Alzheimers Dis; 2016; 50(4):1109-23. PubMed ID: 26890753
[TBL] [Abstract][Full Text] [Related]
16. The BACE1 inhibitor verubecestat (MK-8931) reduces CNS β-amyloid in animal models and in Alzheimer's disease patients.
Kennedy ME; Stamford AW; Chen X; Cox K; Cumming JN; Dockendorf MF; Egan M; Ereshefsky L; Hodgson RA; Hyde LA; Jhee S; Kleijn HJ; Kuvelkar R; Li W; Mattson BA; Mei H; Palcza J; Scott JD; Tanen M; Troyer MD; Tseng JL; Stone JA; Parker EM; Forman MS
Sci Transl Med; 2016 Nov; 8(363):363ra150. PubMed ID: 27807285
[TBL] [Abstract][Full Text] [Related]
17. BACE1 Inhibitor Lanabecestat (AZD3293) in a Phase 1 Study of Healthy Japanese Subjects: Pharmacokinetics and Effects on Plasma and Cerebrospinal Fluid Aβ Peptides.
Sakamoto K; Matsuki S; Matsuguma K; Yoshihara T; Uchida N; Azuma F; Russell M; Hughes G; Haeberlein SB; Alexander RC; Eketjäll S; Kugler AR
J Clin Pharmacol; 2017 Nov; 57(11):1460-1471. PubMed ID: 28618005
[TBL] [Abstract][Full Text] [Related]
18. A therapeutic antibody targeting BACE1 inhibits amyloid-β production in vivo.
Atwal JK; Chen Y; Chiu C; Mortensen DL; Meilandt WJ; Liu Y; Heise CE; Hoyte K; Luk W; Lu Y; Peng K; Wu P; Rouge L; Zhang Y; Lazarus RA; Scearce-Levie K; Wang W; Wu Y; Tessier-Lavigne M; Watts RJ
Sci Transl Med; 2011 May; 3(84):84ra43. PubMed ID: 21613622
[TBL] [Abstract][Full Text] [Related]
19. Relationship between ubiquilin-1 and BACE1 in human Alzheimer's disease and APdE9 transgenic mouse brain and cell-based models.
Natunen T; Takalo M; Kemppainen S; Leskelä S; Marttinen M; Kurkinen KMA; Pursiheimo JP; Sarajärvi T; Viswanathan J; Gabbouj S; Solje E; Tahvanainen E; Pirttimäki T; Kurki M; Paananen J; Rauramaa T; Miettinen P; Mäkinen P; Leinonen V; Soininen H; Airenne K; Tanzi RE; Tanila H; Haapasalo A; Hiltunen M
Neurobiol Dis; 2016 Jan; 85():187-205. PubMed ID: 26563932
[TBL] [Abstract][Full Text] [Related]
20. New BACE1 Chimeric Peptide Inhibitors Selectively Prevent AβPP-β Cleavage Decreasing Amyloid-β Production and Accumulation in Alzheimer's Disease Models.
Resende R; Ferreira-Marques M; Moreira P; Coimbra JRM; Baptista SJ; Isidoro C; Salvador JAR; Dinis TCP; Pereira CF; Santos AE
J Alzheimers Dis; 2020; 76(4):1317-1337. PubMed ID: 32597812
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
